Sarepta Therapeutics (NASDAQ:SRPT) Hits New 52-Week Low – What’s Next?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s share price reached a new 52-week low during trading on Tuesday . The company traded as low as $72.17 and last traded at $73.38, with a volume of 770178 shares traded. The stock had previously closed at $76.33.

Analyst Ratings Changes

SRPT has been the subject of a number of research reports. Piper Sandler decreased their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. Royal Bank of Canada decreased their price objective on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating for the company in a research note on Thursday, February 27th. HC Wainwright reissued a “sell” rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a research report on Wednesday, March 19th. Cantor Fitzgerald restated an “overweight” rating and set a $163.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $202.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Sarepta Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $167.41.

Sarepta Therapeutics Trading Down 3.6 %

The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The firm has a market cap of $7.14 billion, a P/E ratio of 58.89 and a beta of 0.79. The business’s 50 day moving average is $106.35 and its 200-day moving average is $117.47.

Insider Transactions at Sarepta Therapeutics

In related news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the transaction, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 7.70% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of SRPT. Capital International Investors increased its holdings in shares of Sarepta Therapeutics by 38.9% in the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock valued at $1,057,482,000 after acquiring an additional 2,437,855 shares during the last quarter. Norges Bank bought a new stake in Sarepta Therapeutics during the fourth quarter valued at $126,315,000. Wellington Management Group LLP increased its stake in Sarepta Therapeutics by 32.3% during the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after purchasing an additional 665,087 shares during the last quarter. Erste Asset Management GmbH acquired a new stake in shares of Sarepta Therapeutics during the third quarter worth $79,425,000. Finally, Janus Henderson Group PLC lifted its position in shares of Sarepta Therapeutics by 14.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock worth $544,408,000 after buying an additional 543,143 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.